CN105101984A - 丙氨酸-谷氨酰胺、透明质酸和燕麦提取物的协同组合以及其在用于愈合伤口和修复皮肤损伤的组合物中的用途 - Google Patents
丙氨酸-谷氨酰胺、透明质酸和燕麦提取物的协同组合以及其在用于愈合伤口和修复皮肤损伤的组合物中的用途 Download PDFInfo
- Publication number
- CN105101984A CN105101984A CN201480020226.6A CN201480020226A CN105101984A CN 105101984 A CN105101984 A CN 105101984A CN 201480020226 A CN201480020226 A CN 201480020226A CN 105101984 A CN105101984 A CN 105101984A
- Authority
- CN
- China
- Prior art keywords
- combination
- hyaluronic acid
- ala
- extract
- gln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 28
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 28
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 28
- 230000035876 healing Effects 0.000 title claims abstract description 20
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 14
- 206010052428 Wound Diseases 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims description 20
- 231100000444 skin lesion Toxicity 0.000 title abstract 2
- 206010040882 skin lesion Diseases 0.000 title abstract 2
- 239000011885 synergistic combination Substances 0.000 title description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 108010044940 alanylglutamine Proteins 0.000 claims description 28
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 claims description 25
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 claims description 25
- 230000012292 cell migration Effects 0.000 claims description 20
- 210000002510 keratinocyte Anatomy 0.000 claims description 15
- 210000003491 skin Anatomy 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 9
- 208000028990 Skin injury Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 206010039580 Scar Diseases 0.000 claims description 2
- 206010053615 Thermal burn Diseases 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 108010016626 Dipeptides Proteins 0.000 abstract description 3
- 229960002648 alanylglutamine Drugs 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940037201 oris Drugs 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- -1 2-aminovaleroyl amino Chemical group 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 101100537665 Trypanosoma cruzi TOR gene Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229930188798 avenacoside Natural products 0.000 description 1
- AAJHVVLGKCKBSH-JJVNYPDASA-N avenacoside A Natural products O(C[C@@]1(C)O[C@]2([C@H](C)[C@@H]3[C@]4(C)[C@H]([C@H]5[C@@H]([C@]6(C)C(=CC5)C[C@@H](O[C@@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O7)[C@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 AAJHVVLGKCKBSH-JJVNYPDASA-N 0.000 description 1
- XNKSKPFVXMYCKU-QTPGKRPGSA-N avenacoside A Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(O[C@](C)(CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XNKSKPFVXMYCKU-QTPGKRPGSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymers & Plastics (AREA)
Abstract
本发明涉及包含二肽L-丙氨酰-L-谷氨酰胺、透明质酸或其一种盐和燕麦提取物的组合，有利地用于愈合伤口和修复皮肤损伤。
Description
技术领域
本发明涉及包含二肽L-丙氨酰-L-谷氨酰胺、透明质酸或其一种盐和燕麦提取物的协同组合，有利地用于愈合伤口和修复皮肤损伤。
背景技术
愈合是一系列局部防御现象，在侵袭(外伤、烧伤、皮肤病学的行为、外科手术)之后发生。来自血液和组织的大量活性产物在这些现象中释放：酶、各种蛋白质、组胺等。愈合包括几个步骤，其第一步是血液的凝固，停止出血。血液中的白细胞清除死亡细胞。然后存活的细胞进行增殖并产生新组织，该组织的外观取决于损伤的位置。
愈合取决于多种因素，特别是营养、代谢、内分泌或用药(médicamenteux)；愈合的拖延在营养不良或老年受试者中观察到，或在长期服用肾上腺皮质激素的情况中观察到。随着年龄的增长，改善愈合和恢复皮肤损伤的过程实际上变得不太有效，该过程更慢了。
仍然存在提供新的组合物用于皮肤损伤的快速和美学修复的需求。
在文献中描述的、经口服途径施用的二肽L-丙氨酰-L-谷氨酰胺的药理学性质有很多。
其中，二肽L-丙氨酰-L-谷氨酰胺作为给运动者的补充剂经口使用，以促进训练(l’effort)后和外科手术后的恢复，减少住院时间。
这个二肽也在肠外营养中推荐，在需要谷氨酰胺摄入的恢复患者中，作为氨基酸或肠外营养中使用的其他混合物的标准溶液的补充物。
发明内容
在本发明中，发明人以令人惊讶的方式展示了通过局部途径使用的二肽L-丙氨酰-L-谷氨酰胺具有皮肤上的生物活性，基于它的再生特性：对角质细胞迁移的作用。
此外，发明人还展示了当这个二肽与燕麦提取物和透明质酸组合时，这种活性将大大增强。
特别地，发明人证实了对于角质细胞的迁移，三种组分间协同作用的存在，该三种组分为燕麦提取物(更具体地为燕麦苗提取物)、透明质酸或其一种盐以及L-丙氨酰-L-谷氨酰胺。这种活性在组织再生和皮肤损伤的愈合中特别有趣。
事实上，上皮细胞的迁移是发育和组织修复过程(例如胚胎发育和愈合)的重要步骤。
细胞运动的引发(d’initiation)、协调和停止的机制尚未完全阐明，然而细胞迁移的重要作用是公认的。能够刺激该细胞过程的一些药剂已被表征，例如某些基质(matricielles)或胞质蛋白(SANTOROMM.,GAUDINOG.,Cellularandmolecularfacetsofkeratinocytereepithelizationduringwoundhealing.EXP.CELL.RES.304(1):274-286,2005)(WERNERS.,GROSER.Regulationofwoundhealingbygrowthfactorsandcytokines.PHYSIOL.REV.83(3):835-870,2003)(STEFFENSENB.,AKKINENL.,LARIAVAH.Proteolyticeventsofwoundhealing-coordinatedinteractionsamongmatrixmetallopteinases(MMPs),integrins,andextracellularmatrixmolecules.CRIT.REV.ORALBIOL.MED.12(5):373-398,2001)。
在皮肤愈合期间和在慢性皮肤炎症感染中，角质细胞被“激活”以进行迁移过程。然后这些细胞看到它们的表型一方面被与胞外基质的相互作用影响，另一方面被细胞-细胞相互作用影响(MCMILLANJ.R.,AKIYAMAM.,SHIMIZUH.Epidermalbasementmembranezonecomponent:ultrastructuraldistributionandmolecularinteractions.JDERMSC.31:169-177,2003)。伤口边缘的基底层的角质细胞迁移至伤口上并覆盖伤口。事实上，角质细胞是与纤连蛋白、间质真皮胶原蛋白(1型)、胶原IV和基底层的层粘连蛋白5接触而活化的。它们也受某些多肽生长因子的调控，例如TGFβ、TGFα和EGF。此外，在角质细胞活化后，细胞因子(IL1，TGFα)和趋化因子(RANTES和IL8)也有助于加快伤口重新形成上皮(ré-épithélisation)的速度(SZABOI.,WETZELM.A.,ROGERSTJ.Cell-Density-RegulatedChemotacticResponsivenessofKeratinocytesInVitro.JINVESTDERMATOL117:1083-1090,2001)。
附图说明
唯一的附图说明了燕麦苗提取物/透明质酸和L-丙氨酰-L-谷氨酰胺及其组合对角质细胞迁移的作用。
具体实施方式
本发明的主题是包含L-丙氨酰-L-谷氨酰胺、透明质酸或其一种盐和燕麦提取物的组合。
术语“L-丙氨酸”指的是(S)-2-氨基丙酸，也称为α-氨基丙酸。L-丙氨酸是一个有轻微非极性和疏水性特征的中性氨基酸。
术语“L-谷氨酰胺”指的是2-氨基戊酰胺酸(l’acide2-aminoglutaramique)。L-谷氨酰胺是半必需的、极性不带电荷的和亲水的氨基酸。
在本发明的特定实施方案中，组合包含高分子量的透明质酸或其一种盐。优选地，分子量为50000至750000Da，优选250000至450000Da。
透明质酸盐优选是透明质酸钠。
根据本发明的实施方式，透明质酸盐有50000至750000Da，优选250000至450000Da的分子量。
在本发明的实施方案中，燕麦提取物从燕麦苗中获得，优选地如WO2010/054879所述。
在本发明的意义之内，“燕麦苗”是指穗头出现之前的燕麦，也就是说在发芽后阶段(发芽后约2周至2个月)的燕麦，而从拔节至穗头出现的阶段不包括在内。“拔节”是指在开花前的生长阶段，其对应于茎的伸长和形成中的穗的长高。次生代谢物在专利申请WO2010/054879中描述，作为燕麦苗提取物的组成成分：黄酮类和燕麦皂苷类型的皂苷。所述提取物的特征在于存在2至15％的黄酮类和0.2至2％的燕麦皂苷A和B。
制备燕麦提取物的方法可以如下：
-干燥和研磨燕麦的部分，优选燕麦苗，
-在有机溶剂中提取，该溶剂选自酮、酯、C1至C4醇以及这些溶剂的任何可混溶比例的混合物，和
-离心或过滤。
有利地，根据本发明的方法的有机溶剂选自丙酮、甲基乙基酮、甲基异丁基酮、乙酸乙酯、C1至C4醇以及这些溶剂的任何可混溶比例的混合物。
然后通过离心或过滤从提取物中分离提取步骤获得的残渣，溶液可以或多或少浓缩直至获得干提取物。
根据本发明的实施方式，在干燥步骤中可以加入载体(support)，该载体相比于提取的干物质的重量比可以在1至75％之间变化。载体可以是糖(例如麦芽糊精、乳糖)、二氧化硅或任何其他美容学上(cosmétologiquement)可接受的载体。
在本发明的另一个实施方案中，将溶液浓缩以获得燕麦汁，其包含60至80％的干物质，优选70％的干物质。
在特定的实施方案中，根据本发明的组合的特征在于透明质酸/燕麦提取物/L-丙氨酰-L-谷氨酰胺重量比分别为2/1/3至2/1/5。
在另一个实施方式中，透明质酸、燕麦苗提取物和L-丙氨酰-L-谷氨酰胺比例分别为重量比2/1/4。
在另一个优选的实施方案中，根据本发明的组合物包含比例分别为2/1/4的透明质酸/燕麦苗提取物/L-丙氨酰-L-谷氨酰胺。
本发明的另一个主题涉及新的皮肤病学或化妆品组合物，其旨在加速皮肤修复以便重新建立皮肤的完整性和质量。
根据本发明的组合物包含作为皮肤病学或化妆品活性成分的透明质酸、燕麦提取物和L-丙氨酰-L-谷氨酰胺的前述组合，并进一步包含至少一种皮肤病学或化妆品学上可接受的赋形剂。
在本发明优选的实施方案中，组合物用于局部施用。
皮肤病学上(药学上)或化妆品学上相容的赋形剂可以是在本领域技术人员公知的那些中的任何赋形剂，目的在于获得以乳剂、霜剂、香膏、油剂、洗液、凝胶、发泡凝胶、软膏、喷雾剂等的形式用于局部施用的组合物。
在优选的实施方案中，组合物是霜剂、软膏的形式。
在实施方案中，根据本发明的组合物包含至少一种其他活性成分。
根据本发明的“活性成分”是指具有皮肤病学或化妆品特性的任何物质。
这种其他活性成分可以特别地选自愈合、舒缓、止痒、抗衰老、抗皱、抗自由基、抗紫外线剂、刺激皮肤大分子的合成或能量代谢的药剂、保湿、抗细菌、抗真菌、消炎、麻醉剂。
优选地，使用愈合和/或舒缓剂。
最后，本发明的另一主题涉及基于透明质酸，燕麦提取物和L-丙氨酰-L-谷氨酰胺的组合的组合物用于治疗和愈合皮肤损伤的用途。
此外，本发明涉及根据本发明的透明质酸，燕麦苗提取物和L-丙氨酰-L-谷氨酰胺的组合用于制备旨在帮助角质细胞迁移的组合物。
根据本发明的组合物用于受损皮肤的护理：
·在侵入行为/治疗之后：有或无缝合的手术行为(撕除手术(exérésis)、削除手术(shavings))、冷冻疗法、激光消融、中度或深度去皮(peelings)、美塑疗法(mésothérapie)、刮除术(curettage)。
·浅表割伤或烧伤的创伤后阶段(posttraumatique)。
·在需要愈合产品的浅表(非侵入型)行为之后，该愈合产品加快皮肤恢复，可在长期使用(直到皮肤的完全修复)。
·在轻微的外观改变之后：浅表擦伤，晒伤。
根据本发明的皮肤和粘膜损伤的治疗可以特别地包括割伤、缝合、擦伤、划伤、刮伤、手术后疤痕或美学后皮肤病学干预(post-actededermatologieesthétique)、浅表烧伤、晒伤的治疗。
此外，本发明涉及根据本发明的化妆品组合物旨在改善皮肤愈合和修复的用途。
阅读以下的结果将更好地理解本发明，该结果对本发明作出说明但并不限制本发明的范围。
对角质细胞迁移的药理评价
这项测试的目的是评价透明质酸、燕麦苗提取物、L-丙氨酰-L-谷氨酰胺及其组合对角质细胞迁移的作用，该测试使用Oris细胞迁移测定试剂盒(PlatypusTechnologies)。
生物材料
使用了自发性无限增殖的HaCaT人类角质细胞系，该细胞系在文献中经常作为参考模型引用。
细胞迁移方案
用于研究细胞迁移的方案以96孔试剂盒，Oris细胞迁移测定试剂盒(PlatypusTechnologies-TEBU)的使用为基础，实现了这种细胞过程的微型化和量化。
这项测试的原理在于研究向着96孔板的孔的中心的细胞迁移。其包括在孔中放置挡块，以形成2mm直径的检测区。然后当细胞已正确粘附在挡块周围的表面时将挡块移除，从而使细胞能够向着检测区迁移。移除挡块的有活性成分的板在DMEM(Dulbecco'sModifiedEagleMedium)0％SVF(胎牛血清)中于37℃孵育24小时。分析位于区域中细胞的数量，所述区域为挡块所在的区域，以评价细胞的迁移。蒙片(cache)使得独特地显示和计数位于这个区域中的细胞成为可能。对于每种条件，以6至8个孔确定平均值。
在不含SVF的培养基中孵育细胞。
测试的产品
-EGF：33ng/ml，
-燕麦苗提取物：10或30μg/ml，
提取物的制备：
用100ml丙酮/水(80/20)(v/v)提取溶剂提取10g磨碎的幼苗。
过滤并用提取溶剂冲洗残渣。
蒸发丙酮并获得水相。
过滤。通过干燥浓缩直至获得干燥提取物。
-透明质酸钠(分子量250-450kDa)：20或60μg/ml，
-L-丙氨酰-L-谷氨酰胺：40或90μg/ml。
结果的分析
结果表示为：
-与已迁移细胞的数量成正比的荧光强度(IF)。
-相比于对照0％SVF的百分比活性。
统计分析
对粗迁移值进行了Dunnett检验统计分析。然后这项检验给出“p值”的值，表征了不同条件下获得的结果的显著性。显著性的程度定为
p<0.05(*显著)
p<0.01(**非常显著)
p<0.001(***极显著)
p>0.05(不显著)。
结果
燕麦苗提取物、透明质酸和L-丙氨酰-L-谷氨酰胺，单独或组合，在不同浓度下对角质细胞迁移的作用的结果被编入表1和2中，然后显示于唯一附图中。显示于这条曲线上的荧光强度值对应于6至8次测量的平均值，所述测量在3次独立操作代表的实验中进行。
在DMEM和0％SVF存在下，EGF实验的阳性对照确实诱导了角质细胞的迁移。在这些实验条件下，单独的燕麦苗提取物(10或30μg/ml)和单独的透明质酸(20或60μg/ml)对角质细胞迁移没有任何显著作用。另一方面，它们的组合看起来显示了增加迁移的趋势：相比于对照+45％或+27％，随测定的浓度而变化(表1和2)。
单独的L-丙氨酰-L-谷氨酰胺以浓度依赖的方式诱导角质细胞迁移。这些诱导甚至比EGF阳性对照更为重要。3种活性成分——燕麦苗提取物，透明质酸和L-丙氨酰-L-谷氨酰胺——的组合以非常重要和统计学显著的方式诱导角质细胞迁移。表1和2以及唯一附图显示相比于对照这些诱导是统计学显著的，而相比于单独的燕麦苗提取物和单独的透明质酸或相比于其组合这些诱导也是统计学显著的。
唯一附图显示了燕麦苗干燥提取物(ES)、透明质酸(AH)、L-丙氨酰-L-谷氨酰胺(Ala-Glu)及其组合对角质细胞迁移的作用。百分比对应于相对于对照的额外活性百分比。
表1：燕麦苗干燥提取物(ES)、透明质酸(AH)、L-丙氨酰-L-谷氨酰胺(A-G)及其组合对角质细胞迁移的作用。
DS：标准差，**p<0.01相比于对照。
表2：燕麦苗干燥提取物(ES)、透明质酸(AH)、L-丙氨酰-L-谷氨酰胺(A-G)及其组合对角质细胞迁移的作用。
DS：标准差，*p<0.05，**p<0.01相比于对照。
| 组别 | 浓度 | 平均值±DS | ％迁移 |
| 对照 | 1729±384 | 100 | |
| EGF | 33ng/ml | 3553±1556 | 301* |
| ES | 30μg/ml | 1386±226 | 62 |
| AH | 60μg/ml | 1735±488 | 101 |
| A-G | 90μg/ml | 2586±1092 | 194 |
| ES+AH | 30+60μg/ml | 1152±541 | 127 |
| ES+AH+A-G | 30+60+90μg/ml | 2877±1024 | 317** |
因此，燕麦苗提取物、透明质酸或其一种盐和L-丙氨酰-L-谷氨酰胺的组合以协同的方式增加角质细胞的迁移。这些结果证实在皮肤病学或化妆品的愈合组合物中使用这样的组合的好处。
组合物的示例：水包油乳剂
Claims (11)
1.包含L-丙氨酰-L-谷氨酰胺、透明质酸或其一种盐和燕麦提取物的组合。
2.根据权利要求1所述的组合，其特征在于所述透明质酸是透明质酸钠片段的形式。
3.根据权利要求2所述的组合，其特征在于所述透明质酸盐片段的分子量为50000至750000Da。
4.根据权利要求1-3中所述的组合，其特征在于所述燕麦提取物从燕麦苗中获得。
5.根据权利要求4所述的组合，其特征在于透明质酸/燕麦苗提取物/L-丙氨酰-L-谷氨酰胺重量比分别为2/1/3至2/1/5。
6.根据权利要求5所述的组合，其特征在于透明质酸/燕麦苗提取物/L-丙氨酰-L-谷氨酰胺比例分别为重量比2/1/4。
7.根据权利要求1-6中所述的组合，其局部使用旨在帮助角质细胞迁移。
8.根据权利要求1-6中所述的组合，其局部使用旨在治疗皮肤损伤。
9.根据权利要求1-6中所述的组合，其局部使用旨在改善皮肤愈合和恢复。
10.皮肤病学或化妆品组合物，其包含作为活性成分的根据权利要求1-6中所述的组合，与至少一种皮肤病学或化妆品学上可接受的赋形剂。
11.根据权利要求10所述的组合物，其用于治疗割伤、缝合、擦伤、划伤、刮伤、手术后疤痕或美学后皮肤病学干预、浅表烧伤、晒伤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1353231 | 2013-04-10 | ||
| FR1353231A FR3004353B1 (fr) | 2013-04-10 | 2013-04-10 | Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine, et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees |
| PCT/EP2014/057224 WO2014167039A1 (fr) | 2013-04-10 | 2014-04-10 | Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105101984A true CN105101984A (zh) | 2015-11-25 |
| CN105101984B CN105101984B (zh) | 2018-06-01 |
Family
ID=48741402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480020226.6A Active CN105101984B (zh) | 2013-04-10 | 2014-04-10 | 丙氨酸-谷氨酰胺、透明质酸和燕麦提取物的协同组合以及其在用于愈合伤口和修复皮肤损伤的组合物中的用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9849154B2 (zh) |
| EP (1) | EP2983691B1 (zh) |
| JP (1) | JP2016515642A (zh) |
| KR (1) | KR102202391B1 (zh) |
| CN (1) | CN105101984B (zh) |
| AU (1) | AU2014253131B2 (zh) |
| BR (1) | BR112015024920A2 (zh) |
| CA (1) | CA2908628C (zh) |
| DK (1) | DK2983691T3 (zh) |
| ES (1) | ES2661908T3 (zh) |
| FR (1) | FR3004353B1 (zh) |
| HK (1) | HK1212924A1 (zh) |
| MX (1) | MX358845B (zh) |
| NO (1) | NO2983691T3 (zh) |
| PL (1) | PL2983691T3 (zh) |
| PT (1) | PT2983691T (zh) |
| RU (1) | RU2665371C2 (zh) |
| WO (1) | WO2014167039A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3066693B1 (fr) | 2017-05-24 | 2020-12-18 | Fabre Pierre Dermo Cosmetique | Composition pour le remodelage des cicatrices |
| KR101899413B1 (ko) * | 2018-05-03 | 2018-09-18 | 주식회사 케어사이드 | 피부 감염의 예방 또는 치료용 조성물 |
| US10500318B1 (en) * | 2018-07-03 | 2019-12-10 | Temple Therapeutics BV | Dosing regimens for treating hypoxia-associated tissue damage |
| KR102022400B1 (ko) * | 2019-04-30 | 2019-09-18 | (주)진셀팜 | 천연 복합 추출물을 유효성분으로 함유하는 안티폴루션 화장료 조성물 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6368579B1 (en) * | 2000-08-08 | 2002-04-09 | Teresa Leigh Barr | Oat protein complex sunblock and method of use |
| FR2926461A1 (fr) * | 2008-01-23 | 2009-07-24 | Jean Noel Thorel | Nouveau facteur de croissance cellulaire d'origine non animale et applications |
| FR2977494A1 (fr) * | 2011-07-08 | 2013-01-11 | Ayawane | Compositions cosmetiques ou pharmaceutiques contenant des acides hyaluroniques de masses moleculaires differentes |
| CN103002903A (zh) * | 2010-06-28 | 2013-03-27 | Ade治疗公司 | 瘢痕疙瘩治疗法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2101724B1 (en) * | 2006-05-11 | 2020-12-02 | Regenics AS | Administration of cellular extracts for rejuvenation |
| FR2938439B1 (fr) | 2008-11-14 | 2013-03-01 | Fabre Pierre Dermo Cosmetique | Extrait de parties aeriennes d'avoine recoltees avant epiaison |
| DE102009029813A1 (de) * | 2009-06-18 | 2010-12-23 | Henkel Ag & Co. Kgaa | Antifalten-Kosmetikum |
| CN101816620B (zh) * | 2010-03-12 | 2011-07-20 | 广州舒泰生物技术有限公司 | 一种美白化妆品及其制备方法和应用 |
| DE102010027180A1 (de) * | 2010-07-14 | 2011-05-26 | Henkel Ag & Co. Kgaa | Nicht-therapeutische Verwendung zum Stammzellenschutz |
| JP2012240993A (ja) * | 2011-05-24 | 2012-12-10 | Q P Corp | 肌弾力性改善剤 |
-
2013
- 2013-04-10 FR FR1353231A patent/FR3004353B1/fr active Active
-
2014
- 2014-04-10 DK DK14716809.0T patent/DK2983691T3/en active
- 2014-04-10 WO PCT/EP2014/057224 patent/WO2014167039A1/fr active Application Filing
- 2014-04-10 CN CN201480020226.6A patent/CN105101984B/zh active Active
- 2014-04-10 PL PL14716809T patent/PL2983691T3/pl unknown
- 2014-04-10 BR BR112015024920A patent/BR112015024920A2/pt not_active IP Right Cessation
- 2014-04-10 AU AU2014253131A patent/AU2014253131B2/en active Active
- 2014-04-10 EP EP14716809.0A patent/EP2983691B1/fr active Active
- 2014-04-10 JP JP2016506968A patent/JP2016515642A/ja not_active Withdrawn
- 2014-04-10 US US14/777,989 patent/US9849154B2/en active Active
- 2014-04-10 KR KR1020157031150A patent/KR102202391B1/ko active IP Right Grant
- 2014-04-10 NO NO14716809A patent/NO2983691T3/no unknown
- 2014-04-10 MX MX2015014265A patent/MX358845B/es active IP Right Grant
- 2014-04-10 CA CA2908628A patent/CA2908628C/fr active Active
- 2014-04-10 ES ES14716809.0T patent/ES2661908T3/es active Active
- 2014-04-10 RU RU2015142443A patent/RU2665371C2/ru active
- 2014-04-10 PT PT147168090T patent/PT2983691T/pt unknown
-
2016
- 2016-01-29 HK HK16101028.6A patent/HK1212924A1/zh unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6368579B1 (en) * | 2000-08-08 | 2002-04-09 | Teresa Leigh Barr | Oat protein complex sunblock and method of use |
| FR2926461A1 (fr) * | 2008-01-23 | 2009-07-24 | Jean Noel Thorel | Nouveau facteur de croissance cellulaire d'origine non animale et applications |
| CN103002903A (zh) * | 2010-06-28 | 2013-03-27 | Ade治疗公司 | 瘢痕疙瘩治疗法 |
| FR2977494A1 (fr) * | 2011-07-08 | 2013-01-11 | Ayawane | Compositions cosmetiques ou pharmaceutiques contenant des acides hyaluroniques de masses moleculaires differentes |
Non-Patent Citations (1)
| Title |
|---|
| 刘彤: "透明质酸及其在化妆品中的应用", 《广州化工》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR3004353A1 (fr) | 2014-10-17 |
| CN105101984B (zh) | 2018-06-01 |
| MX358845B (es) | 2018-09-05 |
| US9849154B2 (en) | 2017-12-26 |
| DK2983691T3 (en) | 2018-03-19 |
| CA2908628A1 (fr) | 2014-10-16 |
| AU2014253131B2 (en) | 2018-11-15 |
| CA2908628C (fr) | 2021-06-08 |
| JP2016515642A (ja) | 2016-05-30 |
| BR112015024920A2 (pt) | 2017-07-18 |
| HK1212924A1 (zh) | 2016-06-24 |
| AU2014253131A1 (en) | 2015-11-05 |
| MX2015014265A (es) | 2016-03-01 |
| FR3004353B1 (fr) | 2015-05-15 |
| KR20150140319A (ko) | 2015-12-15 |
| NO2983691T3 (zh) | 2018-05-12 |
| PT2983691T (pt) | 2018-03-22 |
| ES2661908T3 (es) | 2018-04-04 |
| WO2014167039A1 (fr) | 2014-10-16 |
| EP2983691A1 (fr) | 2016-02-17 |
| RU2015142443A (ru) | 2017-05-19 |
| KR102202391B1 (ko) | 2021-01-12 |
| EP2983691B1 (fr) | 2017-12-13 |
| US20160303181A1 (en) | 2016-10-20 |
| PL2983691T3 (pl) | 2018-05-30 |
| RU2665371C2 (ru) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102421412B (zh) | 含有日本扁柏多糖的皮肤外用组合物 | |
| US10258561B2 (en) | Cosmetic composition containing a brown alga extract, a yeast extract and ascorbic acid | |
| KR20120052012A (ko) | 쌀뜨물 발효액을 이용한 탈모방지용 천연샴푸 | |
| CN103860449B (zh) | 一种具有祛除妊娠纹功效的护肤制品及其制备方法 | |
| CN105101984A (zh) | 丙氨酸-谷氨酰胺、透明质酸和燕麦提取物的协同组合以及其在用于愈合伤口和修复皮肤损伤的组合物中的用途 | |
| JP2011088845A (ja) | インボルクリン発現抑制剤 | |
| KR20220122453A (ko) | 산삼배양근추출물 제조방법과 산삼배양근 추출물로부터 수득한 진세노사이드복합물을 이용한 주름개선용 화장료 조성물 | |
| JP2010024209A (ja) | 皮膚外用剤 | |
| CN114404349A (zh) | 牛犊血和积雪草来源的外泌体组合物及其在皮肤修护中的应用 | |
| CN107929131B (zh) | 抗衰老组合物及其用途 | |
| KR101722615B1 (ko) | 산뽕나무, 한련초, 지구자 추출물을 함유하는 피부 외용제 조성물 | |
| JP4201091B1 (ja) | 保湿剤、抗老化剤、抗酸化剤及び皮膚外用剤 | |
| CN114053164A (zh) | 一种具有抗炎祛痘促进皮肤再生修复功能的精华液及其制备方法 | |
| CN111939099A (zh) | 一种祛痘保湿面膜及其制备方法 | |
| JP5155543B2 (ja) | エンドセリン−１産生抑制剤、ヘキソサミニダーゼ遊離抑制剤、抗炎症用／美白用皮膚外用剤、エンドセリン−１の産生抑制方法及びヘキソサミニダーゼの遊離抑制方法 | |
| JP2011088854A (ja) | インボルクリン発現抑制剤 | |
| CN108113916B (zh) | 一种天然修复肽面膜液及其制备方法 | |
| KR101574591B1 (ko) | 신곡 추출물을 포함하는 상처 치료용 조성물 | |
| KR102637448B1 (ko) | 아토피 피부 개선 화장료, 이의 제조방법 및 이를 포함하는 화장품 | |
| KR101306960B1 (ko) | 홍해삼으로부터의 콜라겐의 분리 방법 | |
| KR102168418B1 (ko) | 황칠나무, 황기 및, 두릅나무 복합 추출물을 포함하는 여성 청결제 조성물 | |
| JP6969041B2 (ja) | 血管内皮型一酸化窒素合成酵素産生促進剤及び経口用組成物 | |
| CN107693779A (zh) | 一种祛疤组合物及其制备方法 | |
| JP2012167048A (ja) | 表皮角化正常化剤 | |
| WO2017057929A1 (ko) | 영실 및 지부자 혼합 추출물을 함유하는 피부노화 방지 및 주름 개선용 화장료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1212924 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1212924 Country of ref document: HK |